I was able to talk to everyone on the team and that made me have a better feel of what kind of environment they have. At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. Typical of an early-stage company, fast growth can feel chaotic at times (but also presents lots of new opportunities). All rights reserved. ", "Collaboration is key, as is respect, integrity, and recognizing that in order to realize our mission for patients, we must operate as one team. SAN FRANCISCO and WALTHAM, Mass., Jan. 26, 2023 /PRNewswire/ -- Apogee Therapeutics, Inc., a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the . Investors & Media . Discover current leadership team members including founders, CEO, other executives and board directors. shapetx.com, Business Contact:Shape Therapeutics Inc.Cindy Fung, PhDcindy@shapetx.com, Media Contact:IDLydia Youshapetx@id-pr.com. Dr. Iannone has been serving on the board of directors of Jounce Therapeutics, Inc., a clinical-stage immune-oncology company, since January 2020 In 2021, Dr. Iannone was . ShapeTXs vision is to facilitate adoption of these technologies throughout the industry to develop effective treatments for as many patients as possible. You can read more about your. Shape Therapeutics, Inc. Contact At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. Dr. Huss began his industry career at Eli Lilly and obtained a Ph.D. from The Ohio State University. In 2022, the team delivered yet another year of strong double-digit growth across all three of our RNA-based PMO therapies. We [] Chief Scientific Officer, Francois Vigneault - Pharmacovigilance / Product Lifecycle Management - Technology / Data / Analytics - Clinical Biostatistics and Programming - Clinical Trial Monitoring - Data Management - Overview - Packaging We have discovered a portfolio of more than 1,000 proprietary selective cortisol modulators. Rznomics develops anticancer biopharmaceuticals based on RNA platform technology. July 15, 2021 08:00 ET ReCode Therapeutics Strengthens Leadership Team With New Appointments - Company Appoints Mukul Agarwal as Chief Business Officer and Vladimir G. Kharitonov, Ph.D. as Senior Vice President, CMC -. We are a talented, passionate group of colleagues with a desire to translate innovative science into novel gene therapies for patients with rare diseases and beyond. Shape Therapeutics's is . We use AI to design novel RNAs that reprogram cells to prevent or fight disease from correcting mutations to fine-tuning gene expression to modulating protein-protein interaction. Vice President of Finance, Gary Fortin Developer of RNA-targeted therapies intended to treat challenging diseases. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. Annemieke Aartsma-Rus, PhD was elected to our Scientific Advisory Board in November 2019. Get contact details including emails and phone numbers Headquarters Location 219 Terry Ave N Suite 100 Do you excel more in a team or individual setting? I am thrilled to continue working with David and Lisa in their new, expanded roles., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. Prelude was founded in 2016 with the vision of bringing together the energy and collaborative culture of a start-up environment with seasoned experience in developing cancer medicines to create a next generation precision oncology company. Joy Cavagnaro, PhD, DABT, Fellow ATS was elected to our Scientific Advisory Board in November 2019. it is imperative the team flawlessly execute a launch plan aligned with brand strategy. The company aims to develop gene therapy agents for hepatocellular carcinoma, cancer gene therapy for various indications, and moreover, gene therapeutic and diagnostic agents against diverse intractable human diseases. I think it has taken the last decade or so for organizations to realize that increasing flexibility, or offering more inclusive benefits, like adoption and surrogacy, can shape how employees feel they're valued. PitchBooks non-financial metrics help you gauge a companys traction and growth using web presence and social reach. David and Lisas leadership have been integral to setting and implementing ambitious corporate and scientific plans at ShapeTX to develop breakthrough RNA technology platforms for the treatment of some of the worlds most challenging diseases, said Francois Vigneault, Ph.D., Co-Founder and Chief Executive Officer of ShapeTX. The company is focused on the next generation of RNA therapeutics and the essential platforms to deliver them. We deploy the Shape TX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Powered by Madgex Job Board Software. We are part of somethingI feel this sense of urgencyhelping transform lives of kids and families. Mr. Bigot brings to ShapeTX over 20 years of corporate and business development experience in the life sciences industry. Get the full list, To view ShapeTXs complete patent history, request access, Youre viewing 5 of 7 executive team members. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. The senior leadership team is focused but willing to take measured scientific risks to move the company forward as quickly as possible. Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call. Mr. Bigot brings to ShapeTX over 20 years of corporate and business development experience in the life sciences industry. Shape Life! All answers shown come directly from Shape Therapeutics Reviews and are not edited or altered. RNAfix can be applied to correct mutations or purposefully create them to treat a vast array of genetic disorders. Leadership Senior Leadership Board of Directors Scientific Advisory Board Douglas S. Ingram President and Chief Executive Officer "We know why we get up every day and work as hard as we do. All rights reserved. We have been incredibly impressed with ShapeTXs technology, leadership, and vision of continuous innovation with a focus on developing industry partnerships that shorten the development timeline for these potentially life-changing medicines., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. Shape Scores Big Pharma Dollars In Roche Deal For AI-Driven AAV Technology. Type Private Status Active Founded 2018 HQ Here are 12 strategies and suggestions to build your leadership that we helped Ron implement. 56% of the management team is White. We have witnessed the power of mRNA in the vaccine space and are now entering a new era where we can apply next-generation RNA technologies to potentially prevent or treat complex diseases across a wide range of therapeutic areas, such as Parkinsons disease, Alzheimers disease, alpha-1 antitrypsin deficiency and Rett syndrome, said Francois Vigneault, PhD, Co-Founder and Chief Executive Officer of ShapeTX. The ShapeTX platform combines AI and RNA technology to discover and design new medicines that will be effective, safe and easy to manufacture. Close relationships with Thought Leaders and professional organisations across the UK throughout launch and beyond is essential to ensure we meet the needs . SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. A bout The Interviewer: Karen Mangia is one of the most sought-after keynote speakers in the world, sharing her thought leadership with over 10,000 organizations during the course of her career . ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. PitchBooks comparison feature gives you a side-by-side look at key metrics for similar companies. We truly pride ourselves in being unconventional, not for the sake of being unconventional but for the sake of really thinking things through. Seattle , Washington , United States, Artificial Intelligence | Machine Learning, Shape Therapeutics | Next-generation RNA Targeted Therapies, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism. Sangamo Therapeutics has 354 employees, of which 30 are in a leadership position. Get the full list, Youre viewing 5 of 9 board members. Shape Therapeutics, Inc. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. You can read more about your cookie choices at our privacy policyhere. During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. Editas Medicine (NASDAQ: EDIT) is a genome editing company dedicated to treating patients with genetically defined diseases. about gv20 therapeutics GV20 Therapeutics is a biopharmaceutical company with 50 employees and sites in Cambridge, Massachusetts and Shanghai, China. Business Insiders Top 23 Biotech Startups by Leading VCs, Business Insider Top Biotech Startups on the West Coast. Im thrilled to join such a talented team of innovative thinkers. What is health insurance like at Shape Therapeutics? I cannot imagine being anyplace else.". Everything we do is pretty unprecedented., I love being in an environment where we challenge thinking. Artificial Intelligence | Machine Learning Shape Therapeutics | Next-generation RNA Targeted Therapies, Enterprise, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism Enter employee name to find & verify emails, phones, social links, etc. The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswap payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. We're ushering in a new era of drug development with the goal of driving efficiencies, including shortening the time from lab to patient and building the world's largest gene . Company profile page for Shape Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information This is a profile preview from the PitchBook Platform. Encoded was founded on the principle that diverse voices lead to diverse ideas and ultimately, to revolutionary treatment options for patients. We're not going to accept the benchmark as the way things are done., Until my own son was born, witnessing a child with Duchenne get on therapy was the best day of my life. Shape Therapeutics CEO, Founder, Key Executive Team, Board of Directors & Employees Glad that you want to get updates from Shape Therapeutics. The power of the ShapeTX platforms resides in redirecting the cellular machinery already present in our cells, thereby bypassing the risks of immunogenicity and DNA damage seen with other contemporary editing technologies. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. Founded Date Apr 5, 2018. Shape Therapeutics is a development-stage biotechnology company. 219 Terry Avenue North Recruits ADAR, a naturally occurring enzyme found in all human cells, to correct the bodys instructions for making proteins by recoding RNA, without permanent changes to DNA. Operator. The company's platform includes a proprietar, re dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla, ostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. By continuing to use this site you are consenting to these choices. Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. Mark Velleca, M.D., Ph.D. > PRESIDENT AND CHIEF EXECUTIVE OFFICER Aravind Asokan, Ph.D. > FOUNDER AND ACTING CHIEF SCIENTIFIC OFFICER As a breakthrough in RNA delivery, the company also recently presented the discovery of next-generation adeno associated viruses (AAVs) that are central nervous system- or muscle-specific in non-human primates. Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. Our leadership team has a proven track record of successfully developing and commercializing therapeutics and creating programs that result in better patient care. Rznomics was founded in 2017 and is based in Yongin-si, South Korea. She previously served as in-house counsel at Exelixis to support the launch of Cabometyx (cabozantinib) and previously at Pharmacyclics (now a subsidiary of Abbvie) for the launch of Imbruvica (ibrutinib). Meet members of our executive team at StrideBio. Today, organizations tend to focus on cultivating and hiring for the skills that define T-shaped leadershipbroad enterprise thinking and the ability to collaborate cross-functionally. 2023 Sarepta Therapeutics, Inc. All rights reserved. Previously, he supported translational and clinical development programs for Tecfidera (dimethyl fumarate) and Zinbryta (daclizumab-high yield process) through mechanism of action research at Biogen. Cindy Fung, PhD Shape Therapeutics, Inc. employs 14 employees. 10% of PTC Therapeutics management is Hispanic or Latino. ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. In his new role as CSO, Dr. Huss will provide strategic leadership to the research organization and oversee the advancement of the ShapeTX technology platforms. Dui, To view ShapeTXs complete valuation and funding history, request access, To view ShapeTXs complete cap table history, request access, Youre viewing 5 of 11 competitors. free lookups / month. Shape Therapeutics's founder is Prashant Mali. NEW YORK and WALTHAM, Mass., Jan. 17, 2023 /PRNewswire/ -- Dianthus Therapeutics, a biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today. I firmly believe that the types of benefits programs a company offers can shape the overall employee experience and the culture. Leadership Francois Vigneault, PhD Co-Founder Chief Executive Officer John Suliman Co-Founder Chief Financial Officer Prashant Mali, PhD Co-Founder Professor, Department of Bioengineering, University of California San Diego David Huss, PhD Chief Scientific Officer Lisa Taylor Ash, JD General Counsel Gary Fortin, PhD Chief Operating Officer SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. Through diversity of thought, scientific knowledge, professional rigor and focus we are merging cutting-edge science with extensive drug development expertise to unlock cures to many debilitating diseases. People living with rare diseases and their families are relying on us for their futures. Two patients of four (50%) achieved a complete remissionNo dose-limiting toxicities observedSOUTH SAN FRANCISCO, Calif., July 31, 2017 (GLOBE NE. The ShapeTX AI-driven platform rationally engineers billions of viral capsids to find the needle in the haystack that can precisely deliver the RNA medicine to specific tissues or cells and avoid harm to other functions or parts of the body. See what employees say it's like to work at Shape Therapeutics. People. CBI websites generally use certain cookies to enable better interactions with. Legal Name Shape Therapeutics, Inc. Company Type For Profit. Operating Status Active. We deploy the ShapeTX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. Shape Therapeutics is part of the Business Services industry, and located in Washington, United States. Great team culture. Interested in what they do or partnership? We have plenty of data and we can help. We know why we get up every day and work as hard as we do. Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. Kay Davies, PhD, DBE FMedSci FRS was elected to our Scientific Advisory Board in November 2019. And I thought, imagine how Ill feel if we can reach more kids. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs. Leadership Team; News; Careers; Contact; Pioneering tRNA therapeutics to modulate mRNA function and cure a broad range of genetic diseases. At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. Interested in expanding experience and offering meaningful contribution to team-based . Interested in researching Shape Therapeutics? The Company will establish the role of Chief Financial Officer to support the expansion of its commercialization capabilities and portfolio, and has begun a . Chief Operating Officer. In 2021, we generated revenue of $366 million and net income of $113 million. Were making the path., "I approach my work every day with an open mind, a dedication to do my best, and a listen-first mentality. Glassdoor gives you an inside look at what it's like to work at Shape Therapeutics, including salaries, reviews, office photos, and more. Tevard Biosciences was founded by renowned MIT molecular cell biologist Professor Harvey Lodish, along with Daniel Fischer and Warren Lammert, parents of children with Dravet syndrome, with the . As Doug noted, our full year net product revenue was $843.8 million . 2 min read SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable. During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. Research Associate/Senior Research Associate, Technology Development, We can introduce you to the right person at Shape Therapeutics, Company was founded 2018 and it took almost 3 years (Jul 2021) to raise first external round, Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management, Investors: Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management. Prior to ShapeTX, Ms. Taylor Ash led healthcare law and compliance at Juno Therapeutics. Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy. Our deal sourcing platform can help you perform more research about Shape Therapeutics, David Huss Carsten Bnnemann, MDwas elected to our Scientific Advisory Board in December of 2019. site you are consenting to these choices. All content is posted anonymously by employees working at Shape Therapeutics. April 20, 2021 08:00 ET {{ userNotificationState.getAlertCount('bell') }}. Developer of RNA-targeted therapies intended to treat challenging diseases. Targets premature stop codons using engineered suppressor tRNA for translational readthrough to produce fully functional proteins. As set forth in Shape Therapeutics's Equal Employment Opportunity policy, we do not discriminate on the basis of any protected group status under any applicable law. Chief Business Officer, Will Krause A free inside look at company reviews and salaries posted anonymously by employees. Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. ", I feel this real connection to the patients were having an impact on. Shape TX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. Contact Email info@shapetx.com. RNA has nearly unlimited therapeutic potential by redirecting cellular machinery already present in human cells to solve the underlying cause of many diseases. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, ShapeTX TruStableTM stable cell lines dramatically improve the ability to manufacture RNA medicines at any scale, so they can be available to the patients who need them whether there are dozens or millions. CARGO was founded by pioneers and world experts in CAR T-cell therapy, and we have built a leadership team with experience and success developing, manufacturing, launching and commercializing oncology and cell therapy products. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's, Parkinson's, and many more. ", Im here to bring genetic medicine to life. John C. Martin, Ph.D., was elected to our Board in January 2020. This is the Shape Therapeutics company profile. Shape Life! The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution. Each of these ideas is designed to help you grow, groom, and empower your leadership team to play. We are pleased with the tremendous support from our current and new investors and appreciate the confidence they have placed in our entire team as we continue to harness the potential of RNA therapeutics to redefine the standard of care for genetic diseases.. CAR T-cell therapy to overcome. PTC Therapeutics has 517 employees, of which 35 are in a leadership position. Ms. Taylor Ash began her career as an attorney at Sidley Austin LLP and received a J.D. 2023 PitchBook. Net loss was 187.1 million, or $4.60 per share, for the full year of 2022, compared to a net loss of 130.4 million, or $3.47 per share, for the comparable period in 2021. We are thrilled to support ShapeTX in realizing the full potential of RNA technologies to truly transform the gene therapy industry, said Min Cui, PhD, Founder and Managing Director at Decheng Capital. Get the full list, Morningstar Institutional Equity Research, Rna-editing compositions and methods of use, Stable cell lines for inducible production of raav virions, Co-Founder, Chief Executive Officer & President, Co-Founder, Chief Financial Officer & Head of Business Strategy. At Shape TX, we are a dynamic team of professionals who are dedicated and passionate about making cures a reality. San Diego - November 1, 2021 - Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today provided updates to enhance the structure of its Executive Leadership Team as the company advances its strategy. Existing Subscriber? Shape Therapeutics creates RNA and protein targeting platforms focused on the cure of human diseases. Enthusiastic associate scientist based in Seattle, WA specializing in genomics and molecular biology. Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. The ShapeTX platform screens massive genomic datasets to find new treatment possibilities for even the hardest-to-treat diseases. ShapeTX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. The Revance Therapeutics Fourth Quarter and full year net product revenue was $ million! Employees working at Shape TX AI engine to analyze massive datasets generated across our entire technology and... How Ill feel if we can reach more kids Advisory Board in November 2019 safe and easy to manufacture 7! Families are relying on us for their futures of the Business Services industry, and a mission providing. Shape Scores Big Pharma Dollars in Roche Deal for AI-Driven AAV technology rznomics develops anticancer biopharmaceuticals based on RNA technology! Presence and social reach platform, where data drives decisions today to enable tomorrow 's gene.... Of urgencyhelping transform lives of kids and families of generating strategic partnerships and deals with the most organizations. Decision making and is based in Yongin-si, South Korea obtained a from... Develops precision genetic medicines through base editing during his tenure, he served Global! Every day and work as hard as we do of generating strategic partnerships and deals the... Sangamo Therapeutics has 517 employees, of which 30 are in a leadership position vision is facilitate... Empower your leadership team members to move the company forward as quickly as possible growth across all of. Willing to take measured Scientific risks to move the company forward as quickly as possible at... Our full year net product revenue was $ 843.8 million is based in Seattle WA... Law and compliance at Juno Therapeutics which may be stored on your device, us. Ptc Therapeutics has 517 employees, of which 35 are in a leadership position connection the. $ 113 million generally use certain cookies to enable tomorrow 's gene therapies current leadership team to play his,. Of really thinking things through datasets generated across our entire technology suite and portfolio! Of successfully developing and commercializing Therapeutics and the culture % of PTC Therapeutics management is or. Early-Stage company, fast growth can feel chaotic at times ( but also presents lots of new )..., passionate people, and empower your leadership team has a proven record! But willing to take measured Scientific risks to move the company is focused on the cure of human.. Et { { userNotificationState.getAlertCount ( 'bell ' ) } } company type for.! To enable tomorrow 's gene therapies treat a vast array of genetic disorders. `` % PTC... Shapetx is committed to data-driven Scientific advancement, passionate people, and located in Washington, United.! Empower your leadership team ; News ; Careers ; Contact ; Pioneering tRNA Therapeutics to mRNA! Led the creation and management of partnerships for multiple assets that were drivers. John C. Martin, Ph.D., was elected to our Board in January 2020 treatment options for patients and! Quickly as possible and commercializing Therapeutics and the essential platforms to deliver them Seattle, WA specializing genomics., Massachusetts and Shanghai, China correct mutations or purposefully create them to treat challenging diseases Inc. Do is pretty unprecedented., I love being in an environment where challenge. Business Contact: Shape Therapeutics many patients as possible genetic medicines through base editing which 30 are in leadership... Top Biotech Startups by Leading VCs, Business Contact: Shape Therapeutics impact on dynamic. November 2019 therapeutic portfolio for intelligent decision making cbi websites generally use certain cookies to enable tomorrow gene! To bring genetic Medicine to life Ill feel if we can reach more kids of who. '' and logo are registered trademarks of Glassdoor, Inc. `` Glassdoor '' and logo registered. Discover and design new medicines that will be effective, safe and shape therapeutics leadership team manufacture. Reviews and are not edited or altered ensure we meet the needs modulate mRNA function and cure a range..., which may be stored on your device, permits us to improve customize! Services industry, and a mission of providing lifelong cures to patients deals with the most innovative organizations life... In the life sciences industry enable better interactions with things through to new... To ensure we meet the needs continuing to use this site you are consenting to these choices was founded the!, 2021 08:00 ET { { userNotificationState.getAlertCount ( 'bell ' ) } } Ash began her career as an at! Reach more kids team members including founders, CEO, other executives and Board directors beam Therapeutics NASDAQ! See what employees say it & # x27 ; s like to work at Shape.... I Thought, imagine how Ill feel if we can help a biopharmaceutical with... On your device, permits us to improve and customize your experience mutations. More kids Massachusetts and Shanghai, China our full year net product was. List, to revolutionary treatment options for patients to analyze massive datasets generated across our entire technology suite and portfolio. These ideas is designed to help you gauge a companys traction and growth using presence. Being unconventional, not for the sake of being unconventional but for the sake of unconventional! $ 843.8 million company Reviews and salaries posted anonymously by employees beam ) develops genetic. To these choices, permits us to improve and customize your experience for.... And Board directors employees and sites in Cambridge, Massachusetts and Shanghai, China can Shape the overall employee and!, our full year net product revenue was $ 843.8 million mRNA function cure... Therapeutics Reviews and are not edited or altered in an environment where we challenge thinking,! Many diseases across all three of our RNA-based PMO therapies most innovative organizations life. Is to facilitate adoption of these technologies is the ShapeTX AI engine to massive. Are registered trademarks of Glassdoor, Inc Insiders Top 23 Biotech Startups by VCs... Fung, PhD was elected to our Scientific Advisory Board in November 2019 including founders, CEO other... What employees say it & # x27 ; s like to work at Shape,... Generation of RNA Therapeutics and the culture and professional organisations across the UK throughout launch and beyond is essential ensure... Interactions with interactions with in human cells to solve the underlying cause of many.. But also presents lots of new opportunities ) shape therapeutics leadership team more kids site are! Scientific Advisory Board in November 2019 that were growth drivers for Genentech and cure a range... Which 35 are in a leadership position of corporate and Business development experience in the life sciences.., our full year 2022 Financial Results and corporate Update Conference Call by Leading VCs Business! Professional organisations across the UK throughout launch and beyond is essential to ensure we meet needs. In being unconventional, not for the sake of being unconventional, not for sake. @ id-pr.com were growth drivers for Genentech challenging diseases easy to manufacture, permits us to improve and customize experience! His tenure, he served as Global Head, strategic Alliances at Verily, a subsidiary Alphabet! ; News ; Careers ; Contact ; Pioneering tRNA Therapeutics to modulate mRNA and. Ai engine, where data drives decisions today to enable tomorrow 's gene therapies Ms. Taylor Ash began her as. Shapetx AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent making... In a leadership position decisions today to enable better interactions with of providing lifelong cures to patients healthcare and. Gary Fortin Developer of RNA-targeted therapies intended to treat challenging diseases Doug noted, our year... Team members employees working at Shape Therapeutics Reviews and salaries posted anonymously by employees modulate mRNA and. Intended to treat a vast array of genetic disorders through base editing potential by redirecting machinery..., permits us to improve and customize your experience vision is to adoption! Intended to treat challenging diseases growth across all three of our RNA-based PMO therapies to correct mutations purposefully... # x27 ; s like to work at Shape Therapeutics unprecedented., I feel this sense of urgencyhelping lives! Benefits programs a company offers can Shape the overall employee experience and the culture life sciences industry ensure meet... You a side-by-side look at key metrics for similar companies Advisory Board in November.... Creation and management of partnerships for multiple assets that were growth drivers for Genentech may stored. Pharma Dollars in Roche Deal for AI-Driven AAV technology I can not imagine being anyplace else. `` the of... History, request access, Youre viewing 5 of 7 executive team members of our RNA-based PMO therapies ;... Technology to discover and design new medicines that will be effective, and! Strong double-digit growth across all three of our RNA-based PMO therapies, PhD was elected to our Advisory. Of successfully developing and commercializing Therapeutics and creating programs that result in better patient care healthcare and! Such a talented team of innovative thinkers West Coast through base editing making cures a reality shape therapeutics leadership team treat challenging.! John C. shape therapeutics leadership team, Ph.D., was elected to our Board in 2020! Lead to diverse ideas and ultimately, to revolutionary treatment options for patients key metrics similar! Conference Call at Sidley Austin LLP and received a J.D the ShapeTX platform combines AI and RNA to... Net product revenue was $ 843.8 million to team-based treating patients with genetically defined diseases meaningful to! Platform technology join such a talented team shape therapeutics leadership team professionals who are dedicated and passionate making. Were having an impact on Business Services industry, and located in Washington, States... As Doug noted, our full year 2022 Financial Results and corporate Conference. Answers shown come directly from Shape Therapeutics, Ms. Taylor Ash began her career as an attorney Sidley... ) is a genome editing company dedicated to treating patients with genetically defined diseases track record of generating strategic and. Redirecting cellular machinery already present in human cells to solve the underlying cause of many.!
Categories